poisar

Stock

Veru Inc. VERU

$2.75-2.14%

Overview

VERU market data

Price History

VERU price chart · 1M
O
2.80
H
2.80
L
2.72
C
2.75
Vol
8,736.00
Source
US equities market feed
Observed
Aug 27, 2026, 12:00 AM
Cadence
Five-minute page cache; daily and stored hourly bars
Status
fresh

Key Stats & Performance

Open
$2.80
Previous Close
$2.81
Day High
$2.80
Day Low
$2.72
52 Week High
$7.23
52 Week Low
$2.06
7 Day Return
+6.38%
30 Day Return
+23.87%
90 Day Return
+16.77%
1 Year Return
+22.22%
Daily Notional Volume
$24K
Latest daily bar volume multiplied by its closing price.

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$2.80
Diluted earnings per share over the trailing twelve months.
Beta
-1.19
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-223.9%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$2.05 – $7.33
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $44.4M · P/B 3.04 · P/S 2.63.

Company News

10 captured
Veru shares are trading higher after the company reported better-than-expected Q3 EPS results.Benzinga · Aug 10, 2026, 3:06 PM
8-K filing — VERU INC. (VERU)SEC EDGAR · Aug 10, 2026, 11:00 AM
Veru Q3 EPS $(0.30) Beats $(0.32) EstimateBenzinga · Aug 10, 2026, 10:35 AM
Veru Says USPTO Issued Notice Of Allowance For Patent Covering Enobosarm Combined With Weight Loss Drugs, With Protection Until At Least October 2044Benzinga · Aug 4, 2026, 12:36 PM
Veru Completes Patient Enrollment In Phase 2b PLATEAU Clinical Trial To Evaluate Effect Of Oral Enobosarm 3 Mg Versus To Treat ObesityBenzinga · Jul 27, 2026, 12:14 PM
Veru Announces $21.8M Sales ATM Program With Oppenheimer, CanaccordBenzinga · Jul 2, 2026, 8:20 PM
Canaccord Genuity Maintains Buy on Veru, Maintains $25 Price TargetBenzinga · Jun 4, 2026, 4:40 PM
Veru Shares Resume TradeBenzinga · Jun 4, 2026, 4:30 PM
Veru Shares Halted On Circuit Breaker To The Upside, Stock Now Up 167.56%Benzinga · Jun 4, 2026, 4:20 PM
Veru Strikes Clinical Supply Agreement With Novo Nordisk To Mull Combination Of Enobosarm With WegovyBenzinga · Jun 4, 2026, 12:40 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock